anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Expose Contradiction

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 14,162
Current window 10,201-10,230
Pages 473
Rows per page 30
Slide function: Expose Contradictionclear collectionreset all
18 30 60

Slide function

10,201-10,230 of 14,162

filter-aware
176
The slide uses social media screenshots to undermine the credibility of a key proponent (Dr. Miller) by showing her own followers are skeptical of the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
178
The slide uses direct quotes from Facebook group members to undermine the perceived efficacy and novelty of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
180
The slide uses screenshots of Facebook group discussions to highlight negative patient experiences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
181
The slide uses screenshots of Facebook group discussions to highlight patient/caregiver concerns that may contradict or exceed official side effect reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
183
The slide uses a process diagram to illustrate the clinical trial flow, highlighting the transition from the failed C601 trial to the C602 withdrawal study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
184
The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
185
The slide uses a red box to highlight the specific data points (weeks 12-16 of the withdrawal period) that the author claims are the basis for the company's efficacy argument.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
186
The slide uses a Q&A format to present evidence of potential trial manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
187
The slide uses a Q&A format to highlight potential data manipulation or questionable internal confidence in clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
188
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
189
The slide uses a Q&A format to present qualitative evidence of investigator misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
190
The slide uses a 'show, don't tell' approach by presenting the actual questionnaire items to demonstrate their inherent subjectivity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
191
The slide uses direct quotes from investigators to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
192
The slide uses a Q&A format to present expert testimony regarding trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
193
The slide serves as a summary of deeper investigative findings regarding clinical trial data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
194
Focuses on trial design bias and potential data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
197
Includes screenshots of FDA Orange Book data and the front page of US Patent 7,572,789.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
199
The slide uses a red arrow to point from the summary list to the specific boxed text in the FDA label excerpt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
201
The slide uses a 'before-after' or 'comparison' logic to undermine the pricing power of the target company (Vykat) by highlighting readily available, cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
202
The slide uses a 'zoom-in' callout technique to highlight a specific claim in a scientific poster and then critiques the lack of supporting evidence for that claim.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
203
The slide uses a screenshot of a video to contrast the company's public claims with the underlying data source.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
204
The slide uses a forensic approach to discredit clinical data, specifically targeting the validity of a poster presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
206
The slide uses a visual callout (yellow box) to highlight the specific data column in the table that contradicts the plotted graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
207
The slide presents a Q&A transcript excerpt highlighting potential fraud and competitive threats.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
208
The slide uses a line chart to visually debunk a competitor's claim about drug absorption kinetics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
211
The slide uses a table to contrast the solubility of different diazoxide forms to undermine the company's rationale for their specific formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
212
The slide uses a combination of a simulated PK model and a clinical study figure to challenge the necessity and efficacy of the DCCR tablet.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
214
The slide uses molecular weight calculations to expose that DCCR is simply a salt form of diazoxide, implying the price premium is unjustified.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit